（原标题：花旗：美高梅中国(02282)业务持续强劲 升目标价至18港元 维持"买入"评级） 智通财经APP获悉，花旗发布研报称，将美高梅中国(02282)目标价从17.1港元上调至18港元，并维 持"买入"评级。即使近期股价上涨，花旗认为该股的估值仍具吸引力，现价相当于2026财年EBITDA倍 数为8.3倍(低于平均值一个标准差以上)。以50%的股息支付率计算，该股提供约4%的股息收益率。 美高梅中国在2025年第二季录得历史新高的税息折旧及摊销前利润(EBITDA)，达25.11亿元，市场份额 为16.6%，EBITDA利润率为29%(均符合管理层指引)。花旗认为，这反映了其竞争力及审慎的支出(特 别是在玩家再投资方面)，尽管金沙中国(01928)的伦敦人名汇及银河娱乐(00027)的嘉佩乐酒店(Capella) 推出了新产品。根据美高梅中国管理层表示，业务势头在2025年7月持续强劲，各业务分部均录得强劲 的交易量。鉴于近期稳健的趋势，花旗预计美高梅中国自2025年7月至2026年中开放的新套房和别墅， 将有助于其至少守住其市场份额。 ...

Group 1 - Gaming stocks are rising against the trend, with MGM China up 6.67% to HKD 16.64, Melco International Development up 4.02% to HKD 5.44, Sands China up 1.82% to HKD 19.06, and Galaxy Entertainment up 1.32% to HKD 38.45 [1] - MGM China reported total revenue of HKD 8.667 billion for Q2, a year-on-year increase of 8.89%, and total revenue of HKD 16.661 billion for the first half of the year, up 2.73% year-on-year [1] - The adjusted EBITDA for Q2 reached HKD 2.511 billion, marking a year-on-year growth of 2.79%, setting a new record [1] Group 2 - Citigroup raised the target price for MGM from HKD 17.1 to HKD 18 while maintaining a "Buy" rating [1] - Citigroup maintains a forecast for July 2025 GGR at MOP 21 billion, which is approximately 86% of the July 2019 level, with a year-on-year growth of 13% [1] - Macquarie recently increased its forecast for total gaming revenue in Macau for 2025 by 5% to MOP 235.7 billion, representing a year-on-year growth of 4% [1]

Group 1 - The gaming stocks are rising against the trend, with MGM China increasing by 6.67% to HKD 16.64, Melco International Development up by 4.02% to HKD 5.44, Sands China rising by 1.82% to HKD 19.06, and Galaxy Entertainment up by 1.32% to HKD 38.45 [1] - MGM China reported total revenue of HKD 8.667 billion for Q2, a year-on-year increase of 8.89%, and total revenue of HKD 16.661 billion for the first half of the year, up 2.73% year-on-year [1] - The adjusted EBITDA for Q2 reached HKD 2.511 billion, marking a year-on-year growth of 2.79%, setting a new record [1] Group 2 - Citigroup raised the target price for MGM from HKD 17.1 to HKD 18 while maintaining a "Buy" rating [1] - Citigroup maintains the forecast for July 2025 gross gaming revenue (GGR) at MOP 21 billion, which is approximately 86% of the July 2019 level, with a year-on-year growth of 13% [1] - Macquarie recently increased its forecast for total gaming revenue in Macau for 2025 by 5% to MOP 235.7 billion, representing a year-on-year growth of 4% [1]

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Group 1 - The core viewpoint of the article highlights the upward trend of Hong Kong gaming stocks, particularly MGM China, which saw a more than 4% increase after its earnings report, reaching a new high for the period [1] - Macquarie has raised its forecast for Macau's total gaming revenue in 2025 by 5% to 235.7 billion, indicating a year-on-year growth of 4% [1] - Following a strong second quarter, Macquarie expects Macau's gaming business to remain robust in the third quarter, supported by the upcoming openings of high-end hotels and elite events [1] Group 2 - Specific stock performance includes MGM China with a 4.1% increase, SJM Holdings up 1.5%, Sands China rising 1.4%, and Galaxy Entertainment gaining 0.5% [1] - MGM China's adjusted EBITDA for the second quarter grew by 2.8% year-on-year to 2.511 billion, with a quarter-on-quarter increase of 6.1%, marking a quarterly record [1] - During the period, MGM China's gaming revenue reached 977 million, reflecting a 10% year-on-year growth, with the overall market share at 16.6%, and specific shares for MGM Macau and MGM Cotai at approximately 6.2% and 10.5% respectively [1]

格隆汇7月29日丨银河娱乐(00027.HK)宣布，银娱将于2025年8月12日（星期二）举行董事会会议，藉以 （其中包括）批准刊发银娱及其附属公司截至2025年6月30日止六个月的未经审核中期业绩公布，考虑 宣派、建议或支付股息（如有）及处理任何其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：27） 香港，二零二五年七月二十九日 GALAXY ENTERTAINMENT GROUP LIMITED 於本公佈日期，銀娛之執行董事為呂耀東先生（主席）、徐應強先生、鄧呂慧瑜女士 及呂慧玲女士；銀娛之非執行董事為張惠彬博士；以及銀娛之獨立非執行董事為顏 志宏先生、葉樹林博士、黃龍德教授及萬卓祺先生。 銀河娛樂集團有限公司 網址： www.galaxyentertainment.com （於香港註冊成立之有限公司） 董事會會議召開日期 銀河娛樂集團有限公司（「銀娛」）之董事會（「董事會」）謹此宣佈，銀娛將於 二零二五年八月十二日（星期二）舉行董事會會議，藉以（其中包括）批准刊發 銀娛及其附屬公司截至二零二五年六月三十日止六個月之未經審核中期業績公佈， 考慮宣派、建議或支付股息（如有）及處理任何其他事項。 承董事會命 銀河娛樂集團有限公司 公司秘書 冼李美華 ...

Group 1: Market Trends - The paper sector continues its upward trend, with Nine Dragons Paper (02689.HK) leading the gains, rising over 9% after announcing a price increase of 30 CNY/ton for corrugated paper and recycled cardboard starting August 1, reflecting an optimized supply-demand structure in the industry [1] - The brokerage sector saw collective strength, with major Chinese brokerages like Dongfang Securities (03958.HK) and Zhongyuan Securities (01375.HK) rising over 6% and 5% respectively, indicating significant capital inflow into the sector [1] - Urban Beauty (02298.HK) surged 13% as its online GMV for 2024 is projected to reach 1.57 billion CNY, marking a 100% year-on-year increase, showcasing the effectiveness of its new retail transformation [1] Group 2: Company Performance - China Duty Free Group (01880.HK) soared 17% after Macquarie's report indicated a narrowing year-on-year revenue decline from 19.5% in Q4 2024 to 11% in Q1 2025, with a stable gross margin of 33% [1] - The gaming sector experienced a broad increase, with companies like 澳博控股 (00880.HK) and 银河娱乐 (00027.HK) rising over 3%, supported by UBS data showing Macau's average daily gaming revenue in July at 683 million MOP, a 14% year-on-year increase [2] - 雍禾医疗 (02279.HK) saw a 13% increase after forming a strategic partnership with Meituan Health to build a medical-grade hair health service system [2] Group 3: Real Estate and Financing - The Hong Kong real estate sector collectively strengthened, with Country Garden (02007.HK) leading with nearly a 10% rise, driven by improved financing conditions as indicated by the People's Bank of China's report showing a recovery in real estate loan growth [3] - Meilan Airport (0357.HK) rose 10% as CITIC Securities highlighted the significance of Hainan's trade opening, which is expected to benefit the local tourism industry [3] Group 4: Gold Sector Decline - The gold sector faced pressure, with companies like 潼关黄金 (00340.HK) and 大唐黄金 (08331.HK) dropping over 4%, attributed to a decline in spot gold prices below 3,380 USD/oz, driven by reduced safe-haven appeal due to easing trade tensions [4] Group 5: US Market Highlights - Futu Holdings (FUTU.US) rose 2.82% after announcing a long-term strategic partnership with Huaxia Fund to promote the integration of traditional finance and blockchain technology [5] - Japanese automotive stocks surged, with Toyota (TM.US) and Honda (HMC.US) rising over 13% following news of a trade agreement reducing tariffs on Japanese cars [6] - Nuclear power stocks in the US saw significant gains, with Oklo Inc (OKLO.US) rising 9.21%, reflecting a growing interest in nuclear energy [5]

编者按：7月21日，小摩发布研究报告指出，对于 2025 年下半年，预计在恒生指数上半年取得 18% 的 美元回报率且相对亚太除日本指数跑赢约 5% 之后，短期内会出现盘整，原因包括不确定的关税风险、 美联储不太可能降息的前景、不及预期的刺激政策以及 8 月疲软的季节性因素。这种潜在的疲软将是一 个买入机会，因为强劲的股票市场融资、南向资金流入以及稳定币领域的创新可能会推动 EPS 修正。 指数目标：将 2025 年底恒生指数的基准 / 乐观 / 悲观目标从之前的 11,600/12,400/10,300 港元上调至 13,000/14,000/11,000 港元，对应回报率分别为 2%/10%/-14%。 中小盘股首选：美高梅中国和中国建筑国际。 | RIC Code | Security Name | CN Name | GICS Sector | Analyst | JPM rating | | --- | --- | --- | --- | --- | --- | | Large caps | | | | | | | 1299.HK | AIA Group Ltd | 友邦保险 | Financial ...

Market Overview - Hong Kong stocks experienced a rebound with all three major indices rising over 1%, closing with the Hang Seng Index up 1.33% at 24,825.66 points and a total trading volume of HKD 238.69 billion [1] - For the week, the Hang Seng Index increased by 2.84%, the Hang Seng China Enterprises Index rose by 3.44%, and the Hang Seng Tech Index gained 5.53% [1] - The recent geopolitical tensions in the Middle East have eased, and there is a marginal improvement in US-China relations, contributing to a recovery in global market risk appetite [1] Blue Chip Performance - ZTO Express (02057) led blue-chip stocks with a rise of 6.51%, closing at HKD 152.1, contributing 6.54 points to the Hang Seng Index [2] - China Life (02628) increased by 5.13%, contributing 11.32 points, while Hansoh Pharmaceutical (03692) rose by 4.49%, contributing 2.86 points [2] - Xinyi Solar (00968) fell by 3.41%, detracting 0.75 points from the index, and Galaxy Entertainment (00027) decreased by 0.93%, detracting 1.2 points [2] Sector Highlights Stablecoin Sector - Stablecoin-related stocks saw significant gains following the US Congress's approval of the Stablecoin Innovation Act, with Yao Cai Securities Financial (01428) rising by 16.93% and Yunfeng Financial (00376) up by 15% [3] - The act aims to establish a clear legal framework for stablecoins, which is expected to enhance the compliance and development of the stablecoin industry [3] AI Sector - AI-related stocks were active, with Huya Technology (01860) rising by 15.56% and Innovation Works (02121) increasing by 10.39% [4] - The recent launch of the K2 model by Moonlight Kimi and OpenAI's ChatGPT Agent has sparked interest in AI advancements, with analysts optimistic about the sector's growth potential [4] Pharmaceutical Sector - The pharmaceutical sector showed strong performance, with Lepu Biopharma (02157) surging by 24.65% and Genscript Biotech (01672) rising by 17.97% [4] - Morgan Stanley noted a significant rebound in China's healthcare sector, with the MSCI China Healthcare Index up approximately 50% this year [5] Brokerage and Insurance Stocks - Brokerage and insurance stocks also saw gains, with GF Securities (01776) up by 5.04% and China Life (02628) increasing by 5.13% [6] - Recent policies aimed at guiding insurance funds towards long-term stable investments are expected to enhance the profitability of insurance companies [6] Notable Stock Movements - China New Economy Investment (00080) surged by 394.38% after announcing a mandatory cash offer for shares [7] - Chuangmeng Tiandi (01119) rose by 30.12% following a profit forecast indicating a turnaround [8] - Dongfang Zhenxuan (01797) increased by 12.78% due to new product launches [9] - CATL (03750) reached a new high, with Goldman Sachs projecting strong revenue and profit growth [10] - Kintor Pharmaceutical (01888) fell by 9.23% after announcing a share placement at a discount [11]